Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed through laboratory testing (tissue or cell samples) to have prostate adenocarcinoma (a specific type of prostate cancer), but not a mixed type that includes a neuroendocrine component.
• People who have prostate cancer that has spread to other parts of the body (metastatic) and is no longer responding to hormone therapy (castration-resistant), with at least one visible spread shown on a scan taken within 28 days before joining.
• People whose cancer has been getting worse, shown by rising PSA blood test levels, growth of tumours in soft tissue, or the appearance of new spots on bone scans, according to specific medical guidelines (confirm with trial site).
• People who have had surgical removal of the testicles or are receiving ongoing hormone-suppression therapy, with testosterone levels confirmed to be at a very low (castrate) level.
• People whose cancer has previously gotten worse during or after treatment with at least one specific type of hormone-blocking drug (such as enzalutamide, abiraterone, apalutamide, or darolutamide).
• People who have received one, and only one, taxane chemotherapy treatment while their cancer was in the castration-resistant stage (a prior taxane given during an earlier hormone-sensitive stage is also allowed, but only if exactly one taxane was also given in the later stage).

Who may not be able to join:

• People who have a history of cancer spreading to the brain or spinal cord, unless the spread was to the lining of the brain only, has been treated, is causing no symptoms, and is considered stable (confirm with trial site).
• People who have had a serious allergic or hypersensitivity reaction to any of the trial medications or similar drugs, or who have a medical reason they cannot take high-dose steroids.
• People who have or have had another cancer that could affect life expectancy or make it harder to assess the prostate cancer, unless that other cancer was fully treated and has been in remission for more than 3 years, or was a type of non-melanoma skin cancer or a surface-level bladder cancer that was adequately treated.
• People who have an active autoimmune disease that has needed systemic (whole-body) treatment within the past 2 years, or any condition that would require immune-suppressing medication during the trial.
• People who have tested positive for HIV.
• People who have a current or past viral hepatitis infection.
• People who have received anti-cancer treatments (such as chemotherapy, targeted therapy, hormonal therapy, or another trial drug) within 28 days before the first trial dose, with some specific exceptions around certain hormone therapies and timing rules (confirm with trial site).
• People who have previously received any therapy that targets a protein called STEAP1.
• People who have previously received any therapy that targets a protein called CD3.
• People who need ongoing daily steroid medication above a low dose threshold, or any other ongoing immune-suppressing treatment.
• People who have taken part in any other clinical trial involving the study drug xaluritamig, even if they did not actually receive that drug.

Important: Always verify eligibility with the trial site directly before applying.